Non-Injectable Insulin Market Size, Share & Trends Analysis Report By Product (Pills, Sprays), By Distribution Channel (Hospital Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2023 To 2030

The non-injectable insulin market comprises various insulin formulations designed for administration without injections. These alternatives offer options for individuals with diabetes who face challenges with conventional injection techniques or have allergies to injections. Non-injectable options include oral, inhalable, patches, and other emerging delivery methods.

Presently, the market offers two non-injectable options; Afrezza and Exubera. However, Exubera was discontinued due to poor sales performance, leaving Afrezza as the sole product available in the market, distinguished by its inhalation delivery method.

The market segmentation is based on different product categories, such as pills, sprays, and others. Distribution channels include hospital pharmacies, online stores, and drug stores. Inhalable route has gained significant traction as an alternative to injectable, with notable products like Afrezza from MannKind Corporation. Afrezza has demonstrated promising results in clinical trials and received regulatory approvals in multiple countries. Its inhalation delivery method has the potential to revolutionize insulin administration and enhance patient adherence to therapy.

Oral route development presents another promising area, although challenges exist due to the breakdown of insulin by the digestive system before entering the bloodstream. Recent advancements in drug delivery technologies and formulations have shown promise, and several companies are actively working on oral products. Similarly, patches, which deliver the product through the skin, have also attracted attention in recent years. While still in the early stages of development, these patches offer a convenient and painless alternative to injectable route.

The non-injectable insulin market currently faces ambiguity as the failure rate in clinical trials is high. For instance, Oramed Pharmaceuticals Inc. recently announced that its product ORMD-0801 did not meet its primary endpoint, although the company is yet to conclude the closure of the clinical trial for ORMD-0801. Similarly, Biocon terminated its phase 1 trial of oral Insulin Tregopil for Type 1 diabetes mellitus in June 2022, while continuing phase 3 trials for Type 2 diabetes mellitus, according to company officials.

Non-Injectable Insulin Market Segmentation

Major companies operating in the non-injectable insulin market include Boston Therapeutics, Inc., Diabetology Ltd., Emisphere Technologies, Inc., Oramed Pharmaceuticals, Inc., Diasome Pharmaceuticals, Inc., Generex Biotechnology Corp., Aerami Therapeutics, Biocon Ltd., Bionova Lifesciences among others.